AstraZenecas weekly-once diabetes drug gets U.S. approval for children – Reuters

July 23 (Reuters) – AstraZeneca Plc (AZN.L) said on Friday its diabetes drug Bydureon was approved in the United States for use in patients as young as age 10 to help reduce blood sugar levels along with diet and exercise.

The drug, chemically called exenatide, is an injectable suspension taken once a week for 10-to 18-year olds who have type-2 diabetes, the most common form of the condition where the body does not produce enough of the sugar-checking hormone, insulin.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr

Our Standards: The Thomson Reuters Trust Principles.